ligands acting on targets

13(S)-HODE is produced by incubation of linoleic acid with plant and mammalian lipoxygenases. Shown to inhibit the adhesion of tumor cells to the endothelium at concentrations around 1 μM,1,2 and down regulates the expression of the IRGpIIb/IIIa

13(S)-Hydroperoxyoctadeca-9Z,11E-dienoic acid (13-HPODE).

13(S)-Hydroperoxyoctadeca-9Z,11E-dienoic acid (13-HPODE).

13(S)-Hydroperoxyoctadeca-9Z,11E-dienoic acid (13-HPODE).

13,14-dehydro-15-cyclohexyl Carbaprostacyclin inhibits the ADP-induced aggregation of human platelets with potency that is comparable to that of carbaprostacyclin.

13,14-dehydro-15-cyclohexyl Carbaprostacyclin inhibits the ADP-induced aggregation of human platelets with potency that is comparable to that of carbaprostacyclin.

13,14-dihydro PGF1α is a potential metabolite of PGF1α. Its biological activity has not been reported. The corresponding compound in the E1 series (13,14-dihydro PGE1) retains biological activity similar to PGE1.

13,14-dihydro PGF1α is a potential metabolite of PGF1α. Its biological activity has not been reported. The corresponding compound in the E1 series (13,14-dihydro PGE1) retains biological activity similar to PGE1.

13,14-dihydro PGF|2α|is the counterpart of PGF|2α|which is saturated on the lower side chain. It causes luteolysis in hamsters with a potency five times greater than PGF|2α|. The ED|50|for 13,14-dihydro PGF|2α|as a luteolytic agent in hamsters is

13,14-dihydro PGF|2α|is the counterpart of PGF|2α|which is saturated on the lower side chain. It causes luteolysis in hamsters with a potency five times greater than PGF|2α|. The ED|50|for 13,14-dihydro PGF|2α|as a luteolytic agent in hamsters is

13,14-dihydro-15(R)-PGE1 is an analog of 13,14-dihydro-PGE1, which has the hydroxyl group at C-15 in the unnatural R configuration.

13,14-dihydro-15(R)-PGE1 is an analog of 13,14-dihydro-PGE1, which has the hydroxyl group at C-15 in the unnatural R configuration.